|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?显示文摘AIM To evaluate the accuracy of endoscopic ultrasound(EUS) in early esophageal cancer(EC) performed in a highvolume tertiary cancer center. METHODS A retrospective review of patients undergoing esophagectomy was performed and patients with c T1 N0 and c T2 N0 esophageal cancer by EUS were evaluated. Patient demographics, tumor characteristics, and treatment were reviewed. EUS staging was compared to surgical pathology to determine accuracy of EUS. Descriptive statistics was used to describe the cohort. Student's t test and Fisher's exact test or χ~2 test was used to compare variables. Logistic regression analysis was used to determine if clinical variables such as tumor location and tumor histology were associated with EUS accuracy.RESULTS Between 2000 and 2015, 139 patients with clinical stage Ⅰ or Ⅱ?A esophageal cancer undergoing esophagectomy were identified. There were 25(18%) female and 114(82%) male patients. The tumor location included the middle third of the esophagus in 11(8%) and lower third and gastroesophageal junction in 128(92%) patients. Ninety-three percent of patients had adenocarcinoma. Preoperative EUS matched the final surgical pathology in 73/139 patients for a concordance rate of 53%. Twenty-nine patients(21%) were under-staged by EUS; of those, 19(14%) had unrecognized nodal disease. Positron emission tomography(PET) was used in addition to EUS for clinical staging in 62/139 patients. Occult nodal disease was only found in 4 of 62 patients(6%) in whom both EUS and PET were negative for nodal involvement. CONCLUSION EUS is less accurate in early EC and endoscopic mucosal resection might be useful in certain settings. The addition of PET to EUS improves staging accuracy. | Carrie Luu Marisa Amaral Jason Klapman Cynthia Harris Khaldoun Almhanna Sarah Hoffe Jessica Frakes Jose M Pimiento Jacques P Fontaine | 2017 | World Journal of Gastroenterology2017，23，46： | 8 |
| 2 | Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization显示文摘AIM To evaluate the value of pre-treatment 18F-FDG PET/CT in patients with HCC following liver radioembolization.METHODS We identified 34 patients with HCC who underwent an FDG PET/CT scan prior to hepatic radioembolization at our institution between 2009 and 2013. Patients wereseen in clinic one month after radioembolization and then at 2-3 mo intervals. We assessed the influence of FDG tumor uptake on outcomes including local liver control(LLC), distant liver control(DLC), time to distant metastases(DM), progression free survival(PFS) and overall survival(OS).RESULTS The majority of patients were males(n = 25, 74%), and had Child Pugh Class A(n = 31, 91%), with a median age of 68 years(46-84 years). FDG-avid disease was found in 19(56%) patients with SUVmax ranging from 3 to 20. Female patients were more likely to have an FDG-avid HCC(P = 0.02). Median follow up of patients following radioembolization was 12 months(1.2-62.8 mo). FDG-avid disease was associated with a decreased 1 year LLC, DLC, DM and PFS(P < 0.05). Using multivariate analysis, FDG avidity predicted for LLC, DLC, and PFS(all P < 0.05).CONCLUSION In this retrospective study, pre-treatment HCC FDGavidity was found to be associated with worse LLC, DLC, and PFS following radioembolization. Larger studies are needed to validate our initial findings to assess the role of F-18-FDG PET/CT scans as biomarker for patients with HCC following radioembolization. | Yazan Abuodeh Arash O Naghavi Kamran A Ahmed Puja S Venkat Youngchul Kim Bela Kis Junsung Choi Benjamin Biebel Jennifer Sweeney Daniel A Anaya Richard Kim Mokenge Malafa Jessica M Frakes Sarah E Hoffe Ghassan El-Haddad | 2016 | World Journal of Gastroenterology2016，22，47： | 3 |
| 3 | Management of borderline resectable pancreatic cancer显示文摘Pancreatic cancer is the fourth most common cause of cancer death in the United States. Surgery remains the only curative option; however only 20% of the patients have resectable disease at the time of initialpresentation. The definition of borderline resectable pancreatic cancer is not uniform but generally denotes to regional vessel involvement that makes it unlikely to have negative surgical margins. The accurate staging of pancreatic cancer requires triple phase computed tomography or magnetic resonance imaging of the pancreas. Management of patients with borderline resectable pancreatic cancer remains unclear. The data for treatment of these patients is primarily derived from retrospective single institution experience. The prospective trials have been plagued by small numbers and poor accrual. Neoadjuvant therapy is recommended and typically consists of chemotherapy and radiation therapy. The chemotherapeutic regimens continue to evolve along with type and dose of radiation therapy. Gemcitabine or 5-fluorouracil based chemotherapeutic combinations are administered. The type and dose of radiation vary among different institutions. With neoadjuvant treatment, approximately 50% of the patients are able to undergo surgical resections with negative margins obtained in greater than 80% of the patients. Newer trials are attempting to standardize the definition of borderline resectable pancreatic cancer and treatment regimens. In this review, we outline the definition, imaging requirements and management of patients with borderline resectable pancreatic cancer. | Amit Mahipal Jessica Frakes Sarah Hoffe Richard Kim | 2015 | World Journal of Gastrointestinal Oncology2015，7，10： | 3 |
| 4 | Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated显示文摘 | Michael D. Chuong Gregory M. Springett Jessica M. Freilich Catherine K. Park Jill M. Weber Eric A. Mellon Pamela J. Hodul Mokenge P. Malafa Kenneth L. Meredith Sarah E. Hoffe Ravi Shridhar | 2013 | International Journal of Radiation Oncology Biology Physics2013，，3： | 1 |
| 5 | Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation显示文摘 | Noman Ashraf Sarah Hoffe Richard Kim | 2013 | The Oncologist2013，，9： | 1 |
| 6 | Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Chemoradiotherapy显示文摘 | Ravi Shridhar Sarah E. Hoffe Khaldoun Almhanna Jill M. Weber Michael D. Chuong Richard C. Karl Kenneth Meredith | 2013 | Annals of Surgical Oncology2013，，9： | 1 |
| 7 | Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy显示文摘 | Daniel C. Fernandez Sarah E. Hoffe James S. Barthel Shivakumar Vignesh Jason B. Klapman Cynthia Harris Khaldoun Almhanna Matthew C. Biagioli Kenneth L. Meredith Vladimir Feygelman Nikhil G. Rao Ravi Shridhar | 2012 | Practical Radiation Oncology2012，，： | 1 |
| 8 | Prognostic Impact of Lymph Node Retrieval and Ratio in Gastric Cancer: a U.S. Single Center Experience显示文摘 | Joyce Wong Shams Rahman Nadia Saeed Hui-Yi Lin Khaldoun Almhanna Ravi Shridhar Sarah Hoffe Kenneth L. Meredith | 2013 | Journal of Gastrointestinal Surgery2013，，12： | 1 |
| 9 | Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated显示文摘 | Michael D. Chuong Gregory M. Springett Jessica M. Freilich Catherine K. Park Jill M. Weber Eric A. Mellon Pamela J. Hodul Mokenge P. Malafa Kenneth L. Meredith Sarah E. Hoffe Ravi Shridhar | 2013 | International Journal of Radiation Oncology, Biology, Physics2013，，3： | 1 |
| 10 | Oto-facio-cervical (OFC) syndrome is a contiguous gene deletion syndrome involving EYA1: molecular analysis confirms allelism with BOR syndrome and further narrows the Duane syndrome critical region to 1?cM显示文摘 | Sarah Rickard Michael Parker William van’t Hoff Angela Barnicoat Isabelle Russell-Eggitt Robin Winter Maria Bitner-Glindzicz | 2001 | Human Genetics2001，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员